Allogene Therapeutics (ALLO) AGM 2026 summary

Opening remarks and agenda

• Meeting commenced at 8:00 A.M. Pacific Time on June 18, 2026, with polls opened for voting on all matters.

• Virtual meeting hosted via Broadridge Financial Solutions, with Board members, management, auditors, and legal counsel present.

• Inspector of Election appointed and sworn in to oversee voting and tally results.

• Quorum established with proxies for approximately 82% of outstanding shares.

Shareholder proposals

• Five proposals presented: election of three Class II Directors, advisory vote on executive compensation, advisory vote on frequency of compensation votes, amendment to increase authorized common stock, and ratification of auditor.

• Board recommended annual frequency for advisory votes on executive compensation and approval of the amendment to increase authorized shares.

Overview of voting outcomes

• Election of three Class II Directors carried.

• Advisory vote on executive compensation approved.

• Stockholders preferred annual advisory votes on executive compensation.

• Amendment to increase authorized common stock from 400 million to 800 million shares approved.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, confirmed.